Update on highly active antiretroviral therapy: progress and strategies
- 1 February 2000
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 54 (1) , 7-12
- https://doi.org/10.1016/s0753-3322(00)88634-5
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1996
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996